Coeptis previously held limited co-development rights to GEAR. In conjunction with the new license agreement, Coeptis has formed a majority-owned subsidiary, called GEAR Therapeutics, to evaluate GEAR ...

ElevateBio has entered into a multi-year collaboration with Amazon's cloud arm to identify treatment targets and new CRISPR systems.

AWS’s framework will speed up the analysis of ElevateBio’s large protein datasets, hinting at promising drug candidates.

ElevateBio will leverage artificial intelligence to expand and accelerate CRISPR discovery, design, and drug development for thousands of complex ...

"As new studies continue to confirm the widespread presence of PFAS in water systems, consumer products, and environmental ...

New York-based Panther Life Sciences Corp. announced a partnership with Pitt BioForge to advance Panther's Microarray Patch ...

ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in ...

“The advancement of LETI-101 validates our gene editing technology and showcases ElevateBio’s ability to power the development of genetic medicines. Combination of our robust tech stack at Life Edit ...

LETI-101 has demonstrated therapeutically relevant reductions of mutant huntingtin (HTT) protein, exceeding 80%, while preserving essential ...

LETI-101 has demonstrated therapeutically relevant reductions of mutant huntingtin (HTT) protein, exceeding 80%, while preserving essential wild-type HTT in a clinically relevant Huntington’s disease ...

Feb. 24, 2025 (GLOBE NEWSWIRE) -- ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines, announced the presentation of new preclinical ...